What it's for (Indications)
- Suxamethonium (succinylcholine), exemplified by the brand Suxam, is a depolarizing neuromuscular blocker primarily indicated for clinical situations demanding rapid and profound skeletal muscle relaxation of short duration.
- Its principal use is in facilitating tracheal intubation, particularly during rapid sequence induction (RSI) in critically ill patients or those with a high risk of pulmonary aspiration, such as individuals with a full stomach or compromised airway reflexes.
- The rapid onset of action, typically within 30-60 seconds, and its relatively short duration of effect (approximately 5-10 minutes) make it an ideal agent for emergent airway management.
- Beyond tracheal intubation, suxamethonium is also indicated for providing transient muscle relaxation during various diagnostic and therapeutic procedures.
- This includes, but is not limited to, facilitating electroconvulsive therapy (ECT) to attenuate motor seizures and minimize the risk of musculoskeletal injury, aiding in the reduction of fractures or dislocations, and assisting in other brief surgical or endoscopic procedures where profound, yet temporary, muscle paralysis is required to optimize operative conditions.
- Its unique pharmacological profile allows for precise control over the duration of muscle relaxation, making it a valuable tool in specific clinical scenarios where rapid recovery of neuromuscular function is advantageous.
Dosage Information
| Type | Guideline |
|---|---|
| Standard | For intravenous or intramuscular use only. Dosage must be individualized after careful assessment of the patient. Accidental administration of neuromuscular blocking agents may be fatal; store succinylcholine chloride injection carefully to minimize the possibility of selecting the wrong product. It must be titrated to effect by or under the supervision of experienced clinicians who are familiar with its actions and with appropriate neuromuscular monitoring techniques. Administration should only be performed by those skilled in the management of airways. |
Safety & Warnings
Common Side Effects
- Patients may experience post-operative muscle pain.
- Other significant adverse reactions include ventricular dysrhythmias, cardiac arrest, hyperkalemia (including hyperkalemic rhabdomyolysis in pediatric patients), anaphylaxis, malignant hyperthermia, bradycardia, increase in intraocular pressure, and prolonged neuromuscular block due to Phase II block and tachyphylaxis.
- Pregnancy risk cannot be ruled out, consult a doctor before use during pregnancy.
- Consult a doctor before using this medication when lactating.
- Avoid driving when taking this medicine as it may affect your ability to drive.
Serious Warnings
- Black Box Warning: WARNING: VENTRICULAR DYSRHYTHMIAS, CARDIAC ARREST, AND DEATH FROM HYPERKALEMIC RHABDOMYOLYSIS IN PEDIATRIC PATIENTS. Acute rhabdomyolysis with hyperkalemia followed by ventricular dysrhythmias, cardiac arrest, and death has occurred after the administration of succinylcholine to apparently healthy pediatric patients who were subsequently found to have undiagnosed skeletal muscle myopathy, most frequently Duchenne muscular dystrophy.
- This medication should be used with extreme caution in patients with cardiac (heart) diseases.
- Malignant hyperthermia, anaphylaxis, hyperkalemia, bradycardia, increased intraocular pressure, and prolonged neuromuscular block are significant risks.
- There is a risk of ventricular dysrhythmias, cardiac arrest, and death from hyperkalemic rhabdomyolysis in pediatric patients, particularly those with undiagnosed skeletal muscle myopathy.
- Extreme caution is advised in patients following major burns, multiple trauma, extensive denervation of skeletal muscle, or upper motor neuron injury due to the risk of severe hyperkalemia and cardiac arrest.
How it Works (Mechanism of Action)
Succinylcholine is a depolarizing neuromuscular blocker. It combines with the cholinergic receptors of the motor end plate to produce depolarization, which may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited as long as adequate concentration of succinylcholine remains at the receptor site. Onset of flaccid paralysis is rapid (less than one minute after intravenous administration) and typically lasts approximately 4 to 6 minutes for a single administration. The paralysis is progressive, initially involving the levator muscles of the face, muscles of the glottis, and finally the intercostals, diaphragm, and all other skeletal muscles.